The geriatric population in the United States possess certain behaviors such as smoking, not being physically active and eating an unhealthy diet. Rising number of the same has aided the overall cancer drugs market. Development of new anti-cancer molecules coupled with favorable government initiatives has assisted the overall growth of the industry. Amongst the drug type, the usage of immune-oncology PD-1 and PD-L1 inhibitors have recently witnessed a rapid growth owing to its remarkable clinical profile and their approval for various cancer types. The same is having a larger penetration as a new treatment option amongst patient suffering from metastatic melanoma. There has been an increased focus on personalized medicine that is in turn, leading to patient segmentation based biomarker status. There were 14 New Active Substance cancer therapeutics that was launched in 2017. They solely catered to targeted therapies. Out of which, 11 therapies got their approval from FDA. However, adverse effects associated with cancer drugs and high cost of the cancer drugs are some of factors that is anticipated to critically impact the global oncology drugs market.
Access the Full Report @ https://www.absolutemarketsinsights.com/reports/Oncology-Drugs-Market-2019-2027-273
Global oncology drugs market was estimated to be US$ 119 billion in 2020 is expected to reach US$ 350.01 billion by 2029, growing at an estimated CAGR of 12.7% over the forecast period.
Breast cancer has the highest share in 2018 and is expected to continue the same trend over the next eight years. One of the product named Neulasta, offered by Amgen, Inc. is being used by women with stage 4 breast cancer. The drug reported to reduce the risk of febrile neutropenia during chemotherapy by 97% compared to a placebo. It has been duly reported that in most cases adjuvant treat .i.e., chemotherapy with combination of drugs is considered a more favorable option compared to single combination. Some of the adjuvant drugs that are used are anthracyclines, taxanes, 5-fluorouracil, cyclophosphamide and carboplatin are the most demanded drug of Oncology Drugs Market.
In terms of revenue, stem cell transplants is expected to witness a considerable CAGR over the forecast period. This procedure restores blood-forming stem cells in people who have had their destroyed in chemotherapy or radiation therapy to treat cancers. There are two main types of stem cell transplants which are autologous and allogeneic. This treatment primarily help people who suffer from lymphoma and leukemia. They may be also used for multiple myeloma and neuroblastoma.
North America region held more than 45% of the overall Oncology Drugs Market and is anticipated to continue the same trend over the forecast period. In terms of penetration, the European Union hold the second position. The highest number of agents which are newly launched cancer drugs from 2011 to 2015 period are available in the United States and Germany. The reimbursement process differs by geography and the reimbursement ranges from 100% to 61% across countries. Also, owing to advances in cancer treatment, the mortality rates has steadily declined across the major developed countries in the recent past. This decline was the highest in France, followed by the United States and Japan. The improvement in the mortality rates is also due to factors such as early diagnosis, rise in screening services along with the introduction of new drugs (agents) that incorporates the diverse action mechanism.
The report provides both, qualitative and quantitative research of Oncology Drugs Market, as well as provides comprehensive insights and favored development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings, specification, pricing, and gross margin.
Some of the players operating in the oncology drugs market are F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Eli Lilly and Company, Novartis AG, Pfizer Inc., Bayer AG, AstraZeneca, Merck & Co., Inc.,CELGENE CORPORATION and Polaris Pharmaceuticals amongst others
Purchase the latest in-depth report @ https://www.absolutemarketsinsights.com/checkout?id=273
Global, Oncology Drugs Market:
- By Indication
- Breast Cancer
- Prostate Cancer
- Basal Cell Cancer
- Skin Cancer (Non-Melanoma)
- Colorectal cancer
- Lung Cancer
- Renal Cancer
- Bladder Cancer
- Lymphoma
- Others
- By Treatment
- Drug Therapies
- Antimetabolites
- Antitumor Antibiotics
- Asparagine-Specific Enzymes
- Bisphosphonates & Biosimilars
- DNA-Damaging Agents (Antineoplastics) and Alkylating Agents
- Inhibitors
- DNA-Repair Enzyme Inhibitors
- Histone Deacetylase Inhibitors
- Janus-Associated Kinase (JAK) Inhibitors
- Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)
- Proteasome Inhibitors
- Tyrosine Kinase Inhibitors
- PD-1 and PD-L1 inhibitors
- Others
- Monoclonal Antibodies
- Others
- Surgery
- Open Surgery
- Minimally Invasive Surgery
- Radiation Therapy
- Chemotherapy
- Immunotherapy
- Chimeric antigen receptor (CAR) T-cell therapy
- Cytokine Treatment
- Donor lymphocyte infusion
- Monoclonal Antibody Treatment
- Others
- Targeted Therapy
- Hormone Therapy
- Stem Cell Transplant
- Autologous stem cell transplantation
- Allogeneic stem cell transplantation
- Reduced-Intensity Allogeneic Stem Cell Transplantation
- Graft-Versus-Host Disease
- Precision Medicine
- Others
- Drug Therapies
- By Region
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Contact Us:
Company: Absolute Markets Insights
Email Id: sales@absolutemarketsinsights.com
Phone: IN +91-740-024-2424, US +1-510-420-1213
Contact Name: Shreyas Tanna
Website: www.absolutemarketsinsights.com
